Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study.
Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study.
复制标题
DOI：
10.1007/s11684-011-0116-z
复制
发表时间：
2011-03-01
影响因子：
8.1
通讯作者：
Han, Zhong Chao
中科院分区：
文献类型：
--
作者：
Jiang, Ranhua;Han, Zhibo;Han, Zhong Chao
间充质干细胞（MSC）已被用于重度糖尿病（一种高发病率和死亡率的慢性疾病）的临床试验。骨髓是人类间充质干细胞的传统来源，但人类胎盘似乎是另一种更容易获得的来源。本研究研究了人胎盘源性间充质干细胞（PD-MSC）对持续时间较长、胰岛细胞功能障碍、胰岛素剂量高、血糖控制不佳的2型糖尿病患者的治疗效果，以评估PDMSC治疗2型糖尿病（T2D）的安全性、有效性和可行性。10例T2D患者静脉滴注PDSC 3次，间隔1个月。每例患者PDSC总数为(1.22-1.51)* 10(6)个/kg，平均1.35 * 10(6)个/kg。所有患者治疗后均随访至少3个月。10例患者的日均胰岛素用量由63.7±18.7 IU降至34.7±13.4 IU （P < 0.05）
Mesenchymal stem cells (MSC) have been used in clinical trials for severe diabetes, a chronic disease with high morbidity and mortality. Bone marrow is the traditional source of human MSC, but human term placenta appears to be an alternative and more readily available source. Here, the therapeutic effect of human placenta-derived MSC (PD-MSC) was studied in type 2 diabetes patients with longer duration, islet cell dysfunction, high insulin doses as well as poor glycemic control in order to evaluate the safety, efficacy and feasibility of PDMSC treatment in type 2 diabetes (T2D). Ten patients with T2D received three intravenous infusions of PDSC, with one month interval of infusion. The total number of PDSC for each patient was (1.22-1.51) * 10(6)/kg, with an average of 1.35 * 10(6)/kg. All of the patients were followed up after therapy for at least 3 months. A daily mean dose of insulin used in 10 patients was decreased from 63.7±18.7 to 34.7±13.4 IU (P